摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2,3,6-tri-O-benzyl-4-O-(2-O-acetyl-6-deoxy-3-O-methyl-7-O-tosyl-5-C-vinyl-β-D-manno-heptopyranosyl)-α-D-glucopyranoside | 1054659-84-5

中文名称
——
中文别名
——
英文名称
methyl 2,3,6-tri-O-benzyl-4-O-(2-O-acetyl-6-deoxy-3-O-methyl-7-O-tosyl-5-C-vinyl-β-D-manno-heptopyranosyl)-α-D-glucopyranoside
英文别名
[(2R,3S,4S,5S,6S)-6-ethenyl-5-hydroxy-4-methoxy-2-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-bis(phenylmethoxy)-2-(phenylmethoxymethyl)oxan-3-yl]oxy-6-[2-(4-methylphenyl)sulfonyloxyethyl]oxan-3-yl] acetate
methyl 2,3,6-tri-O-benzyl-4-O-(2-O-acetyl-6-deoxy-3-O-methyl-7-O-tosyl-5-C-vinyl-β-D-manno-heptopyranosyl)-α-D-glucopyranoside化学式
CAS
1054659-84-5
化学式
C47H56O14S
mdl
——
分子量
877.019
InChiKey
YMESFYWZNYUJRR-NEOGGGBKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.3
  • 重原子数:
    62
  • 可旋转键数:
    22
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    172
  • 氢给体数:
    1
  • 氢受体数:
    14

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Further Evidence for the Critical Role of a Non-Chair Conformation of L-Iduronic Acid in the Activation of Antithrombin
    摘要:
    L-iduronic acid, a conformationally flexible monosaccharide, imparts a remarkable protein adaptability to the glycosammoglycans heparin, heparan sulfate, and dermatan sulfate. The pentasaccharide representing the antithrombin binding site of heparin contains one such L-iduronic acid residue, the conformation of which has been suspected for a long time to be a critical factor in the interaction with antithrombin. We have recently synthesized pentasaccharides containing an Liduronic acid residue conformationally forced to exist within a restricted arc (S-2(0) reversible arrow B-2,B-5 reversible arrow S-5(1)) of the overall pseudorotational circle. We could thus demonstrate that the S-2(0) conformation is adopted upon binding to the protein. In the present work, we now describe the synthesis of a similar pentasaccharide containing a slightly more flexible L-iduronic acid unit with a three-atom bridge between C-2 and C5 of the hexopyranose ring. This pentasaccharide is a better activator of AT-III with respect to blood coagulation factor Xa inhibition. These results confirm that L-iduronic acid adopts an unusual non-chair conformation close to S-2(0) and clearly explains how the unique conformational behavior Of L-iduronic acid is the key to heparin's interaction with AT-III.
    DOI:
    10.1002/1099-0690(200211)2002:21<3595::aid-ejoc3595>3.0.co;2-f
  • 作为产物:
    参考文献:
    名称:
    Further Evidence for the Critical Role of a Non-Chair Conformation of L-Iduronic Acid in the Activation of Antithrombin
    摘要:
    L-iduronic acid, a conformationally flexible monosaccharide, imparts a remarkable protein adaptability to the glycosammoglycans heparin, heparan sulfate, and dermatan sulfate. The pentasaccharide representing the antithrombin binding site of heparin contains one such L-iduronic acid residue, the conformation of which has been suspected for a long time to be a critical factor in the interaction with antithrombin. We have recently synthesized pentasaccharides containing an Liduronic acid residue conformationally forced to exist within a restricted arc (S-2(0) reversible arrow B-2,B-5 reversible arrow S-5(1)) of the overall pseudorotational circle. We could thus demonstrate that the S-2(0) conformation is adopted upon binding to the protein. In the present work, we now describe the synthesis of a similar pentasaccharide containing a slightly more flexible L-iduronic acid unit with a three-atom bridge between C-2 and C5 of the hexopyranose ring. This pentasaccharide is a better activator of AT-III with respect to blood coagulation factor Xa inhibition. These results confirm that L-iduronic acid adopts an unusual non-chair conformation close to S-2(0) and clearly explains how the unique conformational behavior Of L-iduronic acid is the key to heparin's interaction with AT-III.
    DOI:
    10.1002/1099-0690(200211)2002:21<3595::aid-ejoc3595>3.0.co;2-f
点击查看最新优质反应信息